---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-025878"
form_type: "8-K"
ticker: null
cik: "0001783032"
company_name: "Elevation Oncology, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:30:09.302864+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Elevation Oncology halts EO-3021, lays off 70%, initiates strategic review

## Summary
- Discontinued lead ADC EO-3021 after Phase 1 data showed 22.2% ORR and 72.2% DCR in biomarker-enriched gastric/GEJ cancer patients.
- Reducing workforce by ~70%; estimated $3M in cash costs, majority paid by June 2025. CMO Valerie Jansen departs March 31.
- Advancing EO-1022 (HER3 ADC) with glycan site-specific conjugation; IND filing targeted 2026, preclinical data at AACR 2025.
- Cash, cash equivalents and securities of $93.2M at Dec 31, 2024 fund operations into 2H 2026.
- Evaluating strategic options to maximize shareholder value in parallel with EO-1022 development.

## SEC filing metadata
- accession: 0001104659-25-025878
- form_type: 8-K
- cik: 0001783032
- company_name: Elevation Oncology, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/0001104659-25-025878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/tm259617d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-025878
- JSON: https://secwatch.observer/filing/0001104659-25-025878.json
- Plain text: https://secwatch.observer/filing/0001104659-25-025878.txt

## Key facts
- Executive change
  Valerie M. Jansen departed as Chief Medical Officer at Elevation Oncology, Inc..
  - Action: stepped down
  - Role: Chief Medical Officer
  source text: On March 20, 2025, the Company and Valerie M. Jansen, Chief Medical Officer of the Company, agreed that Dr. Jansen would step down as Chief Medical Officer effective March 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/0001104659-25-025878-index.htm
- Restructurings & Charges
  Elevation Oncology, Inc. announced a restructuring with charges of approximately $3 million affecting entire company (approximately 70%).
  - Type: restructuring
  - Charge: approximately $3 million
  - Affected area: entire company
  - Headcount: approximately 70%
  source text: The total cash payments and costs related to this reduction in force are estimated to be approximately $3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/0001104659-25-025878-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.